Fred Hutchinson Cancer Research Center
University of Washington Cancer Consortium / SCCA
Seattle, WA
Accepting patients
Optimized Cord Blood Transplant
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics
- Cord Blood
- Phase 2
Accepting patients
RALLY-MF
RALLY-MF: A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and AnemiaA Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
- Monoclonal Antibody
- Hemojuvelin (HJV)
- Randomization
- Monotherapy
- Phase 1/2
- Has results
Accepting patients
BH-30236
A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
- CLK Inhibitor
- Phase 1
Accepting patients
Ruxolitinib During Stem Cell Transplant
Peri-Hematopoietic Cell Transplantation Ruxolitinib in Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
- JAK2 Inhibitor
- Allogeneic Stem Cell Transplant
- JAK1 Inhibitor
- Phase 2
Accepting patients
ACCELERATE
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Allogeneic Stem Cell Transplant
- Post-Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
Orca-Q
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Allogeneic Stem Cell Transplant
- Phase 1
Accepting patients
VIP943
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
- Antibody Drug Conjugate (ADC)
- Kinesin Spindle Protein (KSP) Inhibitor
- CD123
- Phase 1
Accepting patients
Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- CLK Inhibitor
- Phase 1/2
Accepting patients
Decitabine Combination Therapy Pre-ASCT
Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study
- Allogeneic Stem Cell Transplant
- Hypomethylating Agents (HMA)
- Chemotherapy
- Phase 1/2
Accepting patients
Combination Chemotherapy Pre-Allogeneic SCT
Pilot Study of FLAG-Ida Followed Immediately by Reduced-Intensity Allogeneic HCT for Adults Age 60 and Older With Newly Diagnosed Adverse-Risk AML or Other High-Grade Myeloid Neoplasm
- Chemotherapy
- Allogeneic Stem Cell Transplant
- Radiation
- Phase 2